Hong Kong · Delayed Price · Currency is HKD RemeGen Statistics
Total Valuation
RemeGen has a market cap or net worth of HKD 65.83 billion. The enterprise value is 60.25 billion.
| Market Cap | 65.83B |
| Enterprise Value | 60.25B |
Important Dates
The last earnings date was Monday, August 24, 2026.
| Earnings Date | Aug 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RemeGen has 559.97 million shares outstanding. The number of shares has increased by 3.88% in one year.
| Current Share Class | 204.27M |
| Shares Outstanding | 559.97M |
| Shares Change (YoY) | +3.88% |
| Shares Change (QoQ) | -1.11% |
| Owned by Insiders (%) | 11.95% |
| Owned by Institutions (%) | 26.87% |
| Float | 344.18M |
Valuation Ratios
The trailing PE ratio is 6.62 and the forward PE ratio is 15.05. RemeGen's PEG ratio is 0.37.
| PE Ratio | 6.62 |
| Forward PE | 15.05 |
| PS Ratio | 7.12 |
| PB Ratio | 6.86 |
| P/TBV Ratio | 6.98 |
| P/FCF Ratio | 13.08 |
| P/OCF Ratio | 12.64 |
| PEG Ratio | 0.37 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.03, with an EV/FCF ratio of 11.97.
| EV / Earnings | 8.96 |
| EV / Sales | 6.52 |
| EV / EBITDA | 10.03 |
| EV / EBIT | 10.65 |
| EV / FCF | 11.97 |
Financial Position
The company has a current ratio of 4.86, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.86 |
| Quick Ratio | 4.23 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.06 |
| Debt / FCF | 0.07 |
| Interest Coverage | 106.50 |
Financial Efficiency
Return on equity (ROE) is 109.10% and return on invested capital (ROIC) is 144.94%.
| Return on Equity (ROE) | 109.10% |
| Return on Assets (ROA) | 39.01% |
| Return on Invested Capital (ROIC) | 144.94% |
| Return on Capital Employed (ROCE) | 57.73% |
| Weighted Average Cost of Capital (WACC) | 6.79% |
| Revenue Per Employee | 2.94M |
| Profits Per Employee | 2.14M |
| Employee Count | 3,145 |
| Asset Turnover | 1.02 |
| Inventory Turnover | 0.70 |
Taxes
In the past 12 months, RemeGen has paid 1.55 million in taxes.
| Income Tax | 1.55M |
| Effective Tax Rate | 0.02% |
Stock Price Statistics
The stock price has decreased by -19.15% in the last 52 weeks. The beta is 0.45, so RemeGen's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | -19.15% |
| 50-Day Moving Average | 80.93 |
| 200-Day Moving Average | 85.61 |
| Relative Strength Index (RSI) | 47.42 |
| Average Volume (20 Days) | 3,991,037 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RemeGen had revenue of HKD 9.24 billion and earned 6.72 billion in profits. Earnings per share was 11.99.
| Revenue | 9.24B |
| Gross Profit | 8.68B |
| Operating Income | 5.66B |
| Pretax Income | 6.72B |
| Net Income | 6.72B |
| EBITDA | 5.94B |
| EBIT | 5.66B |
| Earnings Per Share (EPS) | 11.99 |
Balance Sheet
The company has 5.94 billion in cash and 359.06 million in debt, with a net cash position of 5.58 billion or 9.96 per share.
| Cash & Cash Equivalents | 5.94B |
| Total Debt | 359.06M |
| Net Cash | 5.58B |
| Net Cash Per Share | 9.96 |
| Equity (Book Value) | 9.60B |
| Book Value Per Share | 17.29 |
| Working Capital | 6.07B |
Cash Flow
In the last 12 months, operating cash flow was 5.21 billion and capital expenditures -176.96 million, giving a free cash flow of 5.03 billion.
| Operating Cash Flow | 5.21B |
| Capital Expenditures | -176.96M |
| Depreciation & Amortization | 285.12M |
| Net Borrowing | -2.46B |
| Free Cash Flow | 5.03B |
| FCF Per Share | 8.99 |
Margins
Gross margin is 93.86%, with operating and profit margins of 61.19% and 72.71%.
| Gross Margin | 93.86% |
| Operating Margin | 61.19% |
| Pretax Margin | 72.73% |
| Profit Margin | 72.71% |
| EBITDA Margin | 64.24% |
| EBIT Margin | 61.19% |
| FCF Margin | 53.89% |
Dividends & Yields
RemeGen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.81% |
| Buyback Yield | -3.88% |
| Shareholder Yield | -3.88% |
| Earnings Yield | 10.21% |
| FCF Yield | 7.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for RemeGen is 116.84, which is 47.25% higher than the current price. The consensus rating is "Buy".
| Price Target | 116.84 |
| Price Target Difference | 47.25% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 20.52% |
| EPS Growth Forecast (3Y) | 29.92% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RemeGen has an Altman Z-Score of 23.21 and a Piotroski F-Score of 7.
| Altman Z-Score | 23.21 |
| Piotroski F-Score | 7 |